A beneficial side effect of the medicare drug benefit

New England Journal of Medicine

Volumn 353, Issue 26, 2005, Pages 2742-2743

  Platt, Richard ^a,b   Ommaya, Alexander ^c  

^a HARVARD PILGRIM HEALTH CARE   (United States)

^b HMO Research Network Center for Education and Research in Therapeutics   (United States)

^c INSTITUTE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; VACCINE;

DRUG APPROVAL; DRUG COST; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; HEART INFARCTION; HUMAN; MEDICARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY;

DATABASES, FACTUAL; DRUG THERAPY; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICARE; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 29544445206     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp058297     Document Type: Short Survey

References (4)

1. Guideline for industry: the extent of population exposure to assess clinical safety: for drugs intended for long-term treatment of non-life-threatening conditions. (Accessed December 8, 2005, at http://www.fda.gov/cder/guidance/iche1a.pdf.)
2. Gottlieb S. Opening Pandora's pillbox: using modern information tools to improve drug safety. Health Aff (Millwood) 2005;24:938-48.
3. DeStefano F, Vaccine Safety Datalink Research Group. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf 2001;10:403-6.
4. Centers for Medicare & Medicaid Services. Medicare prescription drug data strategy: improving evidence for patient care through the Medicare prescription drug benefit. (Accessed December 8, 2005, at http://www.cms.hhs. gov/medicarereform/CMSPaper-DataStrategy forMedicareDrugBenefitOverview.pdf.)